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In 1968, Filley et al. [1] made the historical description 
of the pink puffer (emphysematous type with a “cachec-
tic” impression) and the blue bloater (chronic bronchitis 
type with a “metabolic” impression). Hence, for almost 50 
years of literature, the importance of body composition 
in clinical phenotyping of airways disease has been recog-
nized. In 1989, Wilson et al. [2] described that a low body 
weight was related to worse airflow obstruction, worse 
exercise capacity, more hyperinflation, worse diffusion 
capacity, and excess mortality. Ever since then, there was 
substantial and growing interest in nutrition as a deter-
minant of the course and prognosis in chronic obstruc-
tive pulmonary disease (COPD). As it was commonly ob-
served in advanced COPD, in previous years, it was be-
lieved that accelerated weight loss was a unifying concept 
in patients with COPD.
It is now clear that low body weight and ongoing 
weight loss is only present in a proportion of patients with 
COPD. Interestingly, distinct clusters and/or phenotypes 
of patients with COPD can be identified, in which differ-
ences in body weight and body composition are defining 
characteristics [3]. In fact, in COPD, obesity is more prev-
alent compared to underweight [3]. The presence and im-
pact of obesity and metabolic syndrome in subjects with 
COPD have been recognized [4].
Countless studies have documented the importance of 
abdominal obesity and visceral adipose tissue in the de-
velopment of cardiometabolic disease which has led to 
the introduction of waist circumference as a defining fea-
ture of the metabolic syndrome. With cardiovascular dis-
ease as the major comorbidity in COPD, together with the 
increased recognition of obesity in COPD, and the con-
tribution of fat tissue to low-grade systemic inflamma-
tion, a role for fat tissue was seen as a link between COPD 
and its comorbidities. Indeed, it has been postulated that 
the lungs, bone marrow, and adipose tissue form a net-
work, interconnected by vasculature and with significant 
implications for the pathobiology of COPD and, poten-
tially, other chronic noncommunicable diseases that fre-
quently coexist with COPD [5].
A further interest was seen in recent years in the role 
of the visceral fat compartment in COPD. Increased vis-
ceral fat (independent of total fat mass) was found in sub-
jects with COPD compared to matched cohorts [6, 7]. 
Furthermore, a contribution of visceral fat to inflamma-
tory pathways was demonstrated in older persons with 
obstructive lung disease and was associated with in-
creased mortality [6]. COPD patients had increased met-
abolic activity as measured by FDG uptake of the abdom-
inal visceral fat compared to non-COPD subjects. In ad-
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dition, the degree of FDG uptake in the visceral and 
subcutaneous fat independently predicted the inflamma-
tion of the aortic wall [8].
Despite remarkable recent progress in our under-
standing of the complex biology of fat tissue and its rela-
tionship to lung health and disease, the pathophysiologi-
cal interactions between different sources of fat tissue and 
the development of different pulmonary phenotypes are 
less studied.
In this issue of Respiration, Grace et al. [9] report the 
results of their study of thoracic adipose tissue depots 
evaluated using chest computed tomography (CT) scans 
at baseline and after 6 years in 68 current and former 
smokers. They found that the presence of subcutaneous 
but not mediastinal chest fat was associated with less em-
physema progression over time in smokers. In contrast, 
they found that mediastinal fat was associated with a low-
er walking distance and less impairment in walking dis-
tance over time. This single-center observational study 
with a small number of subjects and with only one point 
of follow-up measurement after 6 years needs confirma-
tion and elaboration. In this study it is not possible to ad-
dress causality as also the potential effect of emphysema 
progression on loss of fat tissue needs to be considered. 
Interestingly, lung volume reduction surgery in patients 
with severe emphysema resulted in an increase in both 
body weight and fat-free mass 6 months after surgery 
[10], implying a role of disease-specific features on body 
composition.
However, it is intriguing to speculate that the amount 
of subcutaneous fat has a potential protective effect 
against emphysema progression. Interestingly, previous 
literature corroboratively suggested a role for body com-
position and fat tissue in the pathophysiology of emphy-
sema and/or airway disease, which may also further relate 
to a lung–adipose tissue physiology interaction as postu-
lated here above. A cross-sectional study showed that in-
dependent of airflow obstruction, age, and smoking his-
tory, obesity was negatively associated with the presence 
of emphysema, defined as percentage of low attenuation 
areas below –950 Houndfield units [11]. A Japanese study 
showed that epicardial fat accumulation was indepen-
dently associated with the airway wall thickness in COPD 
patients, but not with low attenuation areas on CT [12]. 
Many studies have suggested that malnutrition and star-
vation may contribute to the development of emphyse-
ma. In a rat model, induced starvation was associated 
with aggravated elastase-induced injury, which was re-
versed with refeeding [13, 14]. Autopsies undertaken on 
starved patients during World War II revealed signs of 
emphysema in relatively young individuals [15]. In addi-
tion, early levels of emphysema have been detected after 
chronic malnutrition, such as in patients with anorexia 
nervosa [16]. Together these data suggest that more pro-
nounced fat deposition may potentially protect against 
the development of emphysema. From this point of view 
it is of interest to evaluate what is known on pathophysi-
ological interactions of proteins produced by adipose tis-
sue, so-called adipokines and development of emphyse-
ma. Dysregulation of adipokines plays a crucial role in a 
variety of metabolic processes, such as obesity. Two key 
adipokines, leptin and adiponectin, are produced mainly 
by adipocytes and have broadly opposing functions [17]. 
In health, leptin acts centrally to induce satiety; however, 
because of leptin resistance, most obese subjects have 
high leptin levels. Adiponectin is the most abundant adi-
pokine and is involved in a wide variety of physiological 
processes. Serum levels of adiponectin decrease with obe-
sity and are positively associated with insulin sensitivity 
[18]. Because of their regulatory role in immune respons-
es and their increased expression by bronchial epithelial 
cells and alveolar macrophages, their potential role in 
COPD-related pathophysiology has been put forward 
[19]. Higher plasma adiponectin levels have been repeat-
edly shown associated with CT-assessed emphysema [20, 
21]. Then again, plasma leptin and the leptin/adiponectin 
ratio, but not adiponectin, were significantly associated 
with changes in CT-assessed emphysema, suggesting a 
potential role as a biomarker in emphysema progression 
[21]. These data suggest a possible contribution of adipo-
kines in the development of emphysema. Although data 
need further in-depth exploration, these findings are in-
triguing as adiponectin-deficient mice seem protected 
against tobacco-induced inflammation and emphysema 
[22].
In order to increase our understanding of the patho-
physiology of COPD and emphysema, we believe it is of 
utmost importance to study interactions of different or-
gan systems, including in-depth evaluation of the biolog-
ical interactions of fat and lung tissue. The study by Grace 
et al. [9] suggests that different fat compartmentation dif-
ferentially impacts on COPD-related disease outcomes 
and potentially progression. Given that chest CT is com-
monly done in COPD-related research, it is emphasized 
to include these measurements of fat compartments as 
study variables. In addition, not only the anatomical pres-
ence and location of fat tissue but also in-depth evalua-
tion of the endocrine and immunological function of fat 
tissue in relation to COPD phenotype-specific patho-
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